Status:
COMPLETED
Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan
Lead Sponsor:
Changhua Christian Hospital
Conditions:
AMD
Eligibility:
All Genders
Brief Summary
Purpose To report the long-term efficacy of patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) in Changhua Christian Hospital...
Detailed Description
INTRODUCTION Neovascular age-related macular degeneration (nAMD) is one of the most common disorders that cause irreversible blindness in the senior population in the developed world. If left untreate...
Eligibility Criteria
Inclusion
- Patients with nAMD that were treated with intravitreal injection of anti-VEGF and had a minimum follow up of 48 months
Exclusion
- Loss follow over 1 year.
Key Trial Info
Start Date :
April 3 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 15 2017
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT03324542
Start Date
April 3 2017
End Date
October 15 2017
Last Update
July 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
鄭**
Changhua, 秀水鄉, Taiwan, 504